Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Limiting metabolic stress by redirecting glucose flux during in vitro expansion improves efficacy of T cell therapies for cancer

ABSTRACT: Adoptive cell therapies for cancer treatment often fail due to a lack of T cell survival and persistence within the patient. Redirecting glycolytic processing with dichloroacetate (DCA) during in vitro expansion improves immediate and long-term T cell engraftment by up to 8x - ultimately resulting in a drastic improvement in tumor clearance. Here we use bulk RNA sequencing to interrogate the changes in transcriptional programs resultant of DCA treatment that may confer the observed improvement in engraftment and tumor clearance of DCA-treated T cells.

ORGANISM(S): Mus musculus

PROVIDER: GSE216666 | GEO | 2023/11/01

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Redirecting glucose flux during in vitro expansion generates epigenetically and metabolically superior anti-tumor T cells for adoptive cell therapies (RNA-Seq)

Project description:Cellular therapies are uniquely living drugs that must survive and persist within the body to achieve anti-tumor efficacy. In vitro culture of therapeutic T cells often relies on hypermetabolic conditions to maximize expansion. We show that this non-physiologic environment generates metabolically and functionally impaired T cells that more readily rely on aerobic glycolysis than T cells found in vivo. To target this shift in glycolytic metabolism, we employ dichloroacetate (DCA) during in vitro expansion resulting in elevated mitochondrial capacity and stemness properties pre-infusion - ultimately improving anti-tumor efficacy. DCA-conditioned T cells surprisingly show no elevated intratumoral function, but have an immediate and long-term survival benefit. DCA conditioning decreases reliance on extracellular glucose by promoting the usage of more physiologic carbon sources. This metabolic shift increases histone acetylation at key longevity genes dependent on citrate export from mitochondria. Blockade of mitochondrial citrate export – and thus formation of cytosolic acetyl-coA – reverses the beneficial effects of DCA. Our data suggest a simple means of correcting in vitro expansion of adoptive cell therapies for enhanced anti-tumor efficacy.

2025-05-30 | GSE249770 | GEO

Redirecting glucose flux during in vitro expansion generates epigenetically and metabolically superior anti-tumor T cells for adoptive cell therapies (CUT&Tag)

2025-05-30 | GSE249769 | GEO

Redirecting glucose flux during in vitro expansion generates epigenetically and metabolically superior anti-tumor T cells for adoptive cell therapies (ATAC-Seq)

2025-05-30 | GSE249768 | GEO

Transcription profiling of lung carcinoma and brain glioblastoma cells were analalyzed, with microarrays run both for control and treatment with dichloroacetate reveals a mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis inhibits cancer growth

Project description:The unique metabolic profile of most cancers (aerobic glycolysis) might confer apoptosis-resistance and be therapeutically targeted. Compared to normal cells, several human cancers have high mitochondrial membrane potential and low expression of the K+ channel Kv1.5, both contributing to apoptosis-resistance. Dichloroacetate (DCA), an inhibitor of the mitochondrial pyruvate dehydrogenase kinase (PDK), shifts metabolism from glycolysis to glucose oxidation, decreases mitochondrial membrane potential, increases mitochondrial-H2O2 and activates Kv channels in all cancer, but not normal cells; DCA upregulates Kv1.5 by an NFAT1-dependent mechanism. DCA induces apoptosis, decreases proliferation and tumor growth in vitro and in vivo, without apparent toxicity. Molecular inhibition of PDK2 by siRNA mimics DCA. The mitochondria-NFAT-Kv axis and PDK are important therapeutic targets in cancer; the orally available DCA is a novel selective anticancer agent. Experiment Overall Design: lung carcinoma and brain glioblastoma cells were analalyzed, with microarrays run both for control and treatment with DCA

2008-06-14 | E-GEOD-6014 | biostudies-arrayexpress

Dichloroacetate and reduced oxygen utilization induced metabolic regulation of the heart: A focus on the cardiac mitochondrial proteome

Project description:Myocardial compensatory mechanisms stimulated by reduced oxygen utilization caused by streptozotocin-induced diabetes mellitus (D) and treated with the dichloroacetate (DCA) are presumably associated with the regulation of mitochondria. We aimed to promote the understanding of key signaling pathways and identify effectors involved in signal transduction.

2022-04-18 | PXD033256 | Pride

A Mitochondria-K+ Channel Axis Is Suppressed in Cancer & Its Normalization Promotes Apoptosis and Inhibits Cancer Growth

2006-10-11 | GSE6014 | GEO

Effects of dichloroacetate on transcriptional networks in rat Schwann cells and primary sensory neurons

Project description:Peripheral neuropathy (PN) is a debilitating side effect of many pharmaceutical agents and is among the most common reasons why patients stop their treatment early. Dichloroacetate (DCA) is a therapeutic drug that inhibits the pyruvate dehydrogenase complex (PDC), thereby modulating metabolic flux in cells. Despite success in improving outcomes of disease, reversible PN has been the single factor limiting the therapeutic potential for DCA. As a result, clinical trials for the drug have been halted prematurely. Establishing toxicity pathways in cells of the peripheral nervous system (PNS) that are involved in DCA-induced PN would provide new opportunities to intervene and mitigate adverse side effects associated with DCA. We investigated the molecular mechanisms underlying DCA-induced injury to both glial and neuronal cells. It was hypothesized that SCs would show activated transcriptional responses associated with oxidative damage and apoptosis at therapeutic doses while these responses will be absent or reduced in DRGs. Experiments were expected to pinpoint molecular mechanisms underlying DCA-induced neurotoxicity, and to reveal the window of therapeutic intervention to reduce side effects associated with DCA in clinical settings.

2024-04-27 | GSE218812 | GEO

Limiting metabolic stress by redirecting glucose flux during in vitro expansion improves efficacy of T cell therapies for cancer

Project description:Limiting metabolic stress by redirecting glucose flux during in vitro expansion improves efficacy of T cell therapies for cancer

| PRJNA894722 | ENA

Redirecting glucose flux during in vitro expansion generates epigenetically and metabolically superior anti-tumor T cells for adoptive cell therapies

Project description:Redirecting glucose flux during in vitro expansion generates epigenetically and metabolically superior anti-tumor T cells for adoptive cell therapies

| PRJNA1050304 | ENA

Redirecting glucose flux during in vitro expansion generates epigenetically and metabolically superior anti-tumor T cells for adoptive cell therapies

Project description:This SuperSeries is composed of the SubSeries listed below.

2025-05-30 | GSE249771 | GEO